Jun 28, 2024 · The GINA 2024 asthma update includes new guidance on medications, monitoring, treatment goals, remission, cough variant asthma, children, and more.

Nov 22, 2024 · The 2025 GOLD COPD report, titled “Global Strategy for Prevention, Diagnosis and Management of COPD: 2025 Report,” can now be downloaded from the GOLD website, along with a pocket guide to the report and the “2025 …

May 29, 2024 · Restrictive lung diseases are respiratory disorders marked by diminished lung capacity stemming from a wide range of underlying factors, including changes in lung parenchyma or conditions that affect the pleura, chest wall, or neuromuscular system. 1 Restrictive lung diseases can be classified as pulmonary parenchyma diseases (intrinsic causes) or extrapulmonary diseases (extrinsic causes ...

Jan 8, 2025 · The Food and Drug Administration (FDA) has approved Zepbound ® (tirzepatide) for the treatment of moderate to severe obstructive sleep apnea (OSA) in adults with obesity.. Zepbound is a dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist.

Jan 8, 2025 · Benralizumab is effective in treating eosinophilic exacerbations in patients with asthma or chronic obstructive pulmonary disease (COPD), according to study findings published in The Lancet Respiratory Medicine.. Investigators hypothesized that in patients with eosinophilic exacerbations, a benralizumab injection, either alone or in combination with prednisolone, would improve outcomes ...

Jan 3, 2025 · Patients hospitalized with health care-associated COVID-19 and those with health care-associated influenza have similar rates of 30-day in-hospital mortality and intensive care unit (ICU) admission, according to study results published in Clinical Infectious Diseases.. Researchers conducted a retrospective cohort study to compare clinical outcomes between adult inpatients who acquired either ...

Dec 8, 2023 · The 2024 GOLD Report, “Global Strategy for Prevention Diagnosis and Management of COPD,” not only includes guideline updates that reflect the latest research on chronic obstructive pulmonary disease (COPD); it also reflects some shifts in thinking about what’s important in COPD treatment, according to Claus Vogelmeier, MD, a lead report author and science committee chair for the Global ...

Jan 10, 2025 · HealthDay News — For patients with chronic obstructive pulmonary disease (COPD), budesonide-glycopyrrolate-formoterol does not improve clinical outcomes compared with fluticasone-umeclidinium-vilanterol, according to a study published online Dec. 30 in The BMJ. William B. Feldman, M.D., M.P.H., from Brigham and Women’s Hospital in Boston, and colleagues compared the effectiveness and ...

Jul 24, 2023 · Investigators found 62% of patients achieved microbiological cure at completion of treatment. These 236 patients had shorter treatment duration (18.4 vs 22.3 months), were less likely to be using 4 or more drugs (8.5% vs 25.3%), had a lower erythrocyte sedimentation rate, and were younger (63 vs 68 years) than the remaining 146 patients who did not achieve a microbiological cure.

Jan 23, 2024 · Pathology of Empyema. Defined as a collection of pus in the thoracic cavity arising from infection in the pleural space, empyema is most commonly caused by bacterial pneumonia and the resulting accumulation of fluid (parapneumonic effusion) in the pleural space. 1 Approximately 20% to 40% of patients who are hospitalized for pneumonia in the United States (US) develop a parapneumonic effusion ...